Redeye reinforces its positive view of Vertiseit following its Q4 report.
Redeye comments on Embracers Q3-report where results where in line with expectations, albeit with so...
After several commercial contracts signed in 2023, Agtira ended the year with a strong cash position...
Redeye comments on Sozap’s Q4 results, which showed higher sales figures than expected, primarily du...
Sprint Bioscience recorded sales improved to SEK 10.
Redeye updates on Invisio following the company’s Q4-results which were stronger than expected with ...
Taaleri's Q4 results were well in line with LSEG Data & Analytics consensus, while the dividend prop...
Redeye retains its positive stance towards Hanza despite a somewhat softer Q4 report than expected, ...
Media still shining, with 24% org. sales and 19% FTD growth Platform & Sportsbook pipeline doubled s...
Earnings lift on better contract terms and cost savings 5% margin-driven EBITA upgrades for '24e-'25...
Redeye comments on Ultimovacs’ Q4 2023 report, with the company having confirmed its intention to co...
Redeye comments on the long-awaited publishing agreement for Autogun Heroes.
CirChem har publicerat bolagets delårsrapport för det fjärde kvartalet 2023 och rapporterar det bäst...
Vaisala’s Q4 EBIT missed our estimates at EUR 16.3m (EUR 17.
Redeye provides a brief comment on Sprint Bioscience’s Q4 report.
Q4 adj. EBITDA sightly below expectations on accelerated costs Strong Media figures across the board...
Redeye comments on GiG’s Q4-results where revenue was slightly higher than expected while EBITDA was...
Redeye provides an initial take on SenzaGen’s H2 2023 report.
Moderating growth rebound expectations for Algo '23e-'25e sales down 7-1% '24e EV/EBITDA of 7x What...
Redeye comments on Fantasma Games ahead of its Q4 results (due 6 March).
